Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If Leo gets a deal, how many shorts will be fried? Looks like Leo has shorts in a headlock.
I don’t think Phase 3 can be skipped, though I hope the same. But, I do think B-OM will be licensed independently of the B platform since it is an oral rinse. That can easily come in the next quarter or two and for a very large upfront payment.
If shareholders sold, what would Aspire and Aruda sell into ?
Leo's got investors caught in a underwater head-lock, trapped in managements Milking Machine.
And with that $450K, they and theirs, are a thirsty bunch.
The Prurisol Trial will be completed within 90 days!!!
Good luck and GOD bless,
George
I agree
Brilacidin Oral Mucositis trial results will be out and show that Brilacidin actually prevents severe oral mucositis.
Final Patient Completes Treatment in Innovation Pharmaceuticals Phase 2 Trial of Brilacidin for Preventing Oral Mucositis in Cancer Patients
Brilacidin
BEVERLY, Mass., October 2, 2017 (GLOBE NEWSWIRE) – Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the last patient has completed study treatment in the Company’s Phase 2 clinical trial of Brilacidin for the prevention and treatment of severe Oral Mucositis (OM) in patients undergoing chemoradiation for Head and Neck Cancer. A total of 61 patients were enrolled in the double-blinded study.
One of the primary objectives of the study (see NCT02324335) is to evaluate the efficacy of Brilacidin in reducing the incidence of severe Oral Mucositis (WHO Grade ≥3) compared to placebo after seven weeks of study treatment. Another primary objective is to assess the safety and tolerability of Brilacidin.
Secondary objectives include evaluating the efficacy of Brilacidin in reducing the duration of severe OM (WHO Grade ≥3) and delaying the onset of severe OM (WHO Grade ≥3).
Interim results released earlier this year (see the March 27, 2017 press release) showed a markedly reduced rate of severe OM (WHO Grade ≥ 3) in patients treated with Brilacidin while undergoing chemoradiation and who received at least 55 Gy cumulative units of radiation.
“The final patient completing study treatment in this Phase 2 clinical trial is yet another achievement in the development of Brilacidin,” commented Arthur P. Bertolino, MD PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Oral mucositis represents a significant treatment challenge to hundreds of thousands of patients and their team of doctors every year. Moreover, costs associated with managing OM place a substantial financial burden on our healthcare system due to a lack of safe and efficacious therapies to not only treat the condition, but prevent it. Over the coming weeks, patients will complete their per-protocol follow up visits after which time the study data will be unblinded. We believe a successful trial for this indication would be a medical breakthrough and likely generate significant interest as the market for a drug that can help prevent severe OM is estimated to be substantial."
Oral Mucositis is a frequent, painful and debilitating complication of chemoradiation commonly manifesting in the treatment of Head and Neck Cancer. Characterized by inflammation and ulceration, patients suffering from OM are often unable to speak or eat (requiring the insertion of a feeding tube) and are more susceptible to bacterial infections, with severe cases leading to hospitalization and increased treatment costs of up to $25,000. There currently are no approved medications for the prevention of OM in this population, with only limited palliative care options available. Worldwide, the potential market for OM is expected to exceed $1 billion in the next few years.
Good luck and GOD bless,
George
Don’t give him a definitive time line like that. He will hold you to it and mock you if it doesn’t happen within that time
The reality is shorts have 4 weeks or less to cover.
Agree George. I thought it was about prurisol though.
There's certainly A LOT going on here!
George I think Brilicidin is worth $10B
more conjecture. The reality is any buying is met with even more selling. the volume and OBV have looked horrible for most of this year. not a good sign and not a sign anything good is on the horizon.
this stock is a junk pile because of management
runninggirl2016
We love your posts.
We wish that you would not be limited to just one post per day.
The press release that you referenced is linked below:
http://www.ipharminc.com/press-release/2017/10/2/final-patient-completes-treatment-in-innovation-pharmaceuticals-phase-2-trial-of-brilacidin-for-oral-mucositis
October 2, 2017
Final Patient Completes Treatment in Innovation Pharmaceuticals Phase 2 Trial of Brilacidin for Preventing Oral Mucositis in Cancer Patients
Brilacidin
BEVERLY, Mass., October 2, 2017 (GLOBE NEWSWIRE) – Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the last patient has completed study treatment in the Company’s Phase 2 clinical trial of Brilacidin for the prevention and treatment of severe Oral Mucositis (OM) in patients undergoing chemoradiation for Head and Neck Cancer. A total of 61 patients were enrolled in the double-blinded study.
One of the primary objectives of the study (see NCT02324335) is to evaluate the efficacy of Brilacidin in reducing the incidence of severe Oral Mucositis (WHO Grade ≥3) compared to placebo after seven weeks of study treatment. Another primary objective is to assess the safety and tolerability of Brilacidin.
Secondary objectives include evaluating the efficacy of Brilacidin in reducing the duration of severe OM (WHO Grade ≥3) and delaying the onset of severe OM (WHO Grade ≥3).
Interim results released earlier this year (see the March 27, 2017 press release) showed a markedly reduced rate of severe OM (WHO Grade ≥ 3) in patients treated with Brilacidin while undergoing chemoradiation and who received at least 55 Gy cumulative units of radiation.
“The final patient completing study treatment in this Phase 2 clinical trial is yet another achievement in the development of Brilacidin,” commented Arthur P. Bertolino, MD PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Oral mucositis represents a significant treatment challenge to hundreds of thousands of patients and their team of doctors every year. Moreover, costs associated with managing OM place a substantial financial burden on our healthcare system due to a lack of safe and efficacious therapies to not only treat the condition, but prevent it. Over the coming weeks, patients will complete their per-protocol follow up visits after which time the study data will be unblinded. We believe a successful trial for this indication would be a medical breakthrough and likely generate significant interest as the market for a drug that can help prevent severe OM is estimated to be substantial."
Oral Mucositis is a frequent, painful and debilitating complication of chemoradiation commonly manifesting in the treatment of Head and Neck Cancer. Characterized by inflammation and ulceration, patients suffering from OM are often unable to speak or eat (requiring the insertion of a feeding tube) and are more susceptible to bacterial infections, with severe cases leading to hospitalization and increased treatment costs of up to $25,000. There currently are no approved medications for the prevention of OM in this population, with only limited palliative care options available. Worldwide, the potential market for OM is expected to exceed $1 billion in the next few years.
Good luck and GOD bless,
George
Better off with very low volume. Coiled spring when partnership announced in Dec or Jan
Cabel I assume you are talking about B-OM.
If so then there are 3 weeks left then data crunching starts.
Look at Monday's PR.
Prurisol alone is worth at least $10 billion!!!
http://cellceutix.com/wp-content/uploads/2014/06/Prurisol-Presentation-for-Med-Derm-RD-Workshop_19Sep2016-u.pdf
The psoriasis market alone is growing from $7.49 Billion per year in 2014 to an estimated $9.02 Billion per year in 2019 and Prurisol will be used also for treatment of psoriatic arthritis, rheumatoid arthritis, multiple myeloma and various other diseases and conditions due to the FACT that Prurisol is a potent inhibitor of IL-20.
Good luck and GOD bless,
George
The Prurisol Phase 2b trial has been designed to be powered for statistical significance.
Innovation Pharmaceuticals Completes Full Patient Enrollment in Phase 2b Study of Prurisol for the Oral Treatment of Psoriasis
BEVERLY, Mass., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that it has met the goal of 189 patients enrolled in its ongoingPhase 2b clinical study of Prurisol for the treatment of moderate-to-severe psoriasis. The final number of patients will be up to 199, including those awaiting final screening test results through the end of this week (September 1). Based upon the protocol for 12 weeks of Prurisol treatment and additional patient follow-up for 4 weeks, the study is expected to be completed in Q4 2017, with results to follow thereafter. Prurisol is being developed as a novel, non-biologic, orally-delivered psoriasis drug candidate.
Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals, commented, “The anticipated completion of the Prurisol trial in 2017, in combination with the expected Q4 completion of the Phase 2 trial of Brilacidin-OM for preventing and treating oral mucositis in chemoradiation patients, are significant milestones for the Company and its shareholders. There is a large need in psoriasis treatment for novel therapies, particularly those that are non-biologic and orally-dosed, and which can provide a safe, early, and sustained control of this common and debilitating skin disease. Regarding Brilacidin-OM for Head and Neck Cancer patients being treated with chemoradiation, presently there is no FDA approved drug for preventing severe oral mucositis, a very painful and debilitating disease.”
Study Overview
The randomized, double-blind, parallel-group and placebo-controlled study (see NCT02949388) increases the total daily oral dosing of Prurisol from a previous high of 200 mg, which earlier was shown to be well-tolerated and demonstrated early efficacy, to include oral Prurisol 300 mg per day, oral Prurisol 400 mg per day, and placebo (3:1:3 randomization). Enrolling, in total, approximately 189 patients with moderate-to-severe chronic plaque psoriasis, treatment duration is 12 weeks. Efficacy is being evaluated using the Psoriasis Area and Severity Index (PASI). Innovation Pharmaceuticals believes now is an opportune time to develop an oral treatment for psoriasis. Currently approved treatments, including injectable biologics, are limited, with many options costly, not easily administered, associated with undesirable side effects and/or diminishing effectiveness over time. A novel psoriasis drug, particularly one that is oral, safe and effective, which could expand patient and physician choices for treatment, likely would command significant market value.
http://www.ipharminc.com/press-release/2017/8/28/innovation-pharmaceuticals-completes-full-patient-enrollment-in-phase-2b-study-of-prurisol-for-the-oral-treatment-of-psoriasis
Good luck and GOD bless,
George
Anticipation for sure Cabel. Looking for some pretty impressive numbers myself. And I believe we'll see that some patients will request to stick to prurisol.
All is looking very good for $IPIX
more delays, too small of trials, diluting shareholders, MM's in complete control of trading, officers taking 450k from a company that has no revenue.
I wish I could sell
9 weeks have passed since they stated last patients started dosing,.. Aug 7th.
We need 11 weeks,.. so 2 more weeks and they start crunching the data!!
My wag is 80%,.. up from 77%
BTW, this Positively Outstanding Stock closed up yesterday...
No stairs. There's an exit but if you want a higher floor you must wait for the elevator.
Regarding BOM possible Breakthrough therapy...wondering if phase 3 can be skipped?
Happy Friday. Green close today
Yes, you're talking BS. The company continues to make steady progress through multiple late stage clinical trials. If that continues, significant share price appreciation is simply a matter of time. I'm willing to wait, and am happy that management doesn't concern themselves with short term nonsense.
Oh look, a kitty!!!!!
That is simply ridiculous.
No, I invested my money for the future, I didn't make a day trade which is clearly what you are talking about.
so far he has done a terrible job. look at the IPIX return numbers. he has paid fat salaries that cannot be justified for a small no revenue company - he has abused shareholders with the bill
What total nonsense. Just look at the portfolio of successful trials. They are the future value we shareholders stand to benefit from.
Again what you say is nonsense and lets me believe biotech investing is beyond your understanding.
Short term or long term shareholder value? Leo is doing a wonderful job at focusing on LONG TERM shareholder value, which is by far the most important of the two.
Just like the calls for the company to "buy shares to support stock price". Really? People want the company to squander precious cash reserves in an attempt to manipulate short term stock price? To what end? In exactly what way would diverting money and attention to near term share price move forward the actual company goals of developing valuable, important, life changing drugs that can be sold eventually for billions of dollars?
It's almost like some people look for anything with which to bash the company, no matter how short sighted or unreasonable or transparent. It's almost like there are some people who don't really care about long term success... Can that be?
DOTB
Patience here will pay out in truckloads. I am very confident in that. I wish I could see into the future and know which route will be taken, but I am not a psychic. The next step as you say, wait for 3 phase 2 trials to conclude and for the data.
We've had plenty of sound bites from IPIX that partnership is their priority, that BP knows the value of their pipeline and that BP knows IPIX knows the true value, and we do have CDAs in place with several BPs and that IPIX is the farthest they have ever been in our history in regards to BP and negotiations/talks. All of the above is documented by IPIX.
Taking these promising drugs thru preclinical to now (for some) thru phase 2b is a tip of the cap for me. Not many biotechs can get to this point with one drug and one indication. We have 3 and 1 of those drugs has 3 indications moving thru phase 2 currently.
No one can take that away from us Sox. I will buy 5000 more shares today and again lock it up. That 5000 will go to my niece and most likely pay for her college in 20 years.
Cheers
These things happen, Tom. Even to the great Bull companies like IPIX.
Leo has done a horrid job for shareholder value. That is his main job as a publically held company
Great post and I agree on P. Some shareholders just don't have enough patience to wait for IPIX to maximize shareholder value. Trial takes time and deal takes time. I think the partnership picture will become clearer after top-line results for B-OM, P & K-OC are released.
First up, B-OM. Tick tock...
Dane, I wouldn't mind seeing IPIX....
just start climbing the stairs.
"that will move the stock up or down dramatically"
DOWN ?!? whaddya mean Down ?? lol
More like being trapped in a high rise basement waiting for the elevator to be repaired, waiting on parts that need to be invented, then manufactured in order to fix the elevator which fell from just shy of the $fifth floor.
Nothing to fear at these levels until Prurisol results. That will move the stock up or down dramatically.
Price is holding steady in the 70's waiting room.
like sitting at comfortable bus stop.
The most recent short interest is < 1% of the OS. IMHO interpreting short volume as actual short sales is misleading. Please check out these two posts for some detailed explanations.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132584168
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133263103
The official short interest and failure-to-deliver data can be seen here.
http://otce.finra.org/ESI
https://www.sec.gov/help/foiadocsfailsdatahtm.html
11. I read on an internet chat room or website that a specific security has a large number of fails; are these sources reliable?
Investors can and should verify the number of failures to deliver in a specific security by checking publicly available data on failures to deliver. The Commission publishes on its website failures to deliver data for all equity securities, regardless of the fails level, twice per month. For current failures to deliver information, see http://www.sec.gov/foia/docs/failsdata.htm.
Investors should always be cautious that issuers, promoters, or shareholders may be seeking to stimulate buying interest by making false, misleading or unfounded statements in internet chat rooms or other such forums about alleged large “naked” short positions in some smaller issuers. Some individuals may encourage other investors to buy these issuers’ securities by claiming that there will be an imminent short squeeze, in which the alleged “naked” short sellers will be forced to cover open short positions at increasing prices. These claims in fact may be false.
https://www.sec.gov/investor/pubs/regsho.htm
Such a prankster. Lol. Go IPIX.
FINRA short sales of IPIX
20171005|IPIX|26019|0|108468|O
24% of today's volume was short sales!
Go IPIX!!!
http://regsho.finra.org/FORFshvol20171005.txt
My brokers confirmed all my IPIX shares are real. I can trade or transfer them anytime I want and I've done it in the past.
Why don't you show us where it says naked shorts don't have to cover after a name/CUSIP # change?
Here are the latest short interest and FTD #s.
Settlement Date: 9/15/2017
Current Short: 1,214,089
Previous Short: 1,220,108
Change: -6,019 (-0.49%)
Average Daily Volume: 215,861
Days to Cover: 5.62
http://otce.finra.org/ESI
According to the SEC, only 11,557 shares were failure-to-deliver as of August 31.
20170831|45782D100|IPIX|11557|INNOVATION PHARMACEU|0.70
https://www.sec.gov/data/foiadocsfailsdatahtm
I'd pay the $5 to make it stop...
Very funny.
Is that your stop?
Not a "POS". It's a clinical stage biotech in the middle of several mid to late stage successful trials, with three separate pipelines, where success with any one of their three drugs would rocket the share price of IPIX to the moon.
Hardly a poster child for a typical "pink sheet shell company". I mean seriously.
DOTB
POS? yes Point of Sale. We will all be ringing the register with much cash when IPIX get's to 50.00 or higher.
Followers
|
977
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
402946
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant Minnesinger sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |